#iwAL25 | John DiPersio comments on the challenges of treating T-cell malignancies with bispecific antibody therapy, and shares insights into the development of WU-CART-007, an anti-CD7 allogeneic CAR T-cell product:
🎥 buff.ly/s2zXiCa
#ALLsm #Leusm #ImmunoOnc #HemOnc #BloodSky #HemeSky #MedSky
At #SOHO2025, Sarah Tasian shared insights into the management of Ph-like ALL, highlighting the move toward an individualized, precision medicine approach.
Watch the interview here:
👉 buff.ly/E837gwk 👈
#ALLsm #Leusm #Leukemia #HemOnc #ImmunoOnc #BloodSky #HemeSky #MedSky
At #SOHO2025, we spoke with Nicholas Short of @mdanderson.bsky.social, who shared insight into the prevalence and management of TP53-mutated ALL.🩸
Click here to watch the interview:
👉 buff.ly/NT6gE6I 👈
#ALLsm #Leusm #HemOnc #BloodSky #HemeSky #MedSky @societyofhemonc.bsky.social
In a fantastic interview from #SOHO2025, @bijlshah.bsky.social of @moffittnews.bsky.social shares findings from the five-year analysis of ZUMA-3, in which adult patients with R/R B-ALL were treated with brexu-cel.
Click to watch:
🎥 buff.ly/vSzDTPE
#HemOnc #ALLsm #Leusm #CTSM #TrialUpdate
Today is #WorldLeukemiaDay.🩸
Dive into our disease channels for the latest news & updates in AML, ALL, CLL, CML, & more: 👉 buff.ly/PCXVECQ
Video interviews, podcasts, roundtable discussions, articles – we have it all! 🎥 🗞️ 🎧
#AMLsm #CLLsm #ALLsm #Leusm
Watch our recent interview with Jae Park of @mskcancercenter.bsky.social to hear about the long-term data with obe-cel in ALL & its potential to serve as a standalone treatment for adult R/R B-ALL.
Click here:
👉 buff.ly/inx0gbp
#ALLsm #Leusm #Leukemia #CTSM #CARTCell #ImmunoOnc #HemOnc
Trial S1905
Trial S1905 tests OBI-3424 treatment for patients w relapsed or refractory T-ALL or T-LBL. Phase 1 has completed; phase 2 is now testing for efficacy and toxicities. Also measuring the rate of MRD negativity in patients with CR or CRi. #HemOnc #ALLsm #lymphoma
@fredhutch.bsky.social
The Phase II ITCC-059 study is a trial investigating inotuzumab ozogamicin in pediatric patients with R/R ALL.🧒
Erica Brivio shared the findings in an interview at #EHA2025 - watch here:
👉 buff.ly/XmuoMe9
#ALLsm #Leusm #CTSM #TrialUpdate #Leukemia #BloodSky #HemeSky #MedSky
Could BCL2 inhibition play a role in the management of adult ALL?🤔💭
We asked Marina Konopleva of @einsteinmededu.bsky.social this question in an insightful interview at #EHA2025, and here's what she had to say:
🎥 buff.ly/Qit6tsB
#ALLsm #Leusm #Leukemia #HemOnc #BloodSky #HemeSky #MedSky
Could BCL2 inhibition play a role in the management of adult ALL?🤔💭
We asked Marina Konopleva of @einsteinmededu.bsky.social this question in an insightful interview at #EHA2025, and here's what she had to say:
🎥 buff.ly/SIqp1QY
#ALLsm #Leusm #Leukemia #HemOnc #MedSky #BloodSky #HemeSky
Adolescent & young adult patients with ALL are a distinct group with unique challenges.🩸
Read our new article to learn more & to hear what Wendy Stock & Marlise Luskin think community oncologists should know when treating AYA patients:
📘 buff.ly/PM3pIEj
#Leusm #ALLsm #MedSky #BloodSky #HemOnc
First interview of the #EHA25 Day 2. Dr. Litzow of @MayoClinic #mmsm #allsm Remember stop by and share your research. Hearing about your research provides patients with hope. We are located across from Coral 4!
A Phase I study investigated the use of dasatinib, asciminib, blinatumomab, & prednisone in pts with Ph+ ALL.
We recently spoke with Marlise Luskin of @danafarber.bsky.social to hear the results!
Watch the interview here:
👉 buff.ly/TjdwEcY
#ASCO25 #CTSM #ALLsm #Leusm @ascocancer.bsky.social
Want the latest expert insights about CAR-T in ALL?💉🩸
Then check out our recent discussion from #iwCART25, in which leading experts Claire Roddie, Rebecca Gardner, Bijal Shah, & Noelle Frey provide their insights:
👉 buff.ly/Evw2bXJ
#ALLsm #Leusm #CARTCell #HemOnc #BloodSky #HemeSky #MedSky
MYC is required for tumor maintenance & presents a potential target for the treatment of acute leukemias.🩸
Learn about the development of strategies targeting MYC from Michael Andreeff:
👉 buff.ly/IY0vaTp 👈
#Leusm #AMLsm #ALLsm #ISAL2025 #HemOnc #Hematology #MedSky #BloodSky #HemeSky
Have you listened to our most recent podcast episode?
🔬Explore exciting updates in #CARTcell therapy for ALL! From clinical trial updates to real-world data, this episode covers it all.
Tune in now! 🎧 👉 buff.ly/41zTGp8
#Leusm #ALLsm #ImmunoOnc #CTSM #TrialUpdate #BloodSky #Hemesky #HemOnc
🚨 New podcast alert! 🚨
Dive into the latest on #CARTcell therapy in #ALL, including trial updates, novel approaches & real-world outcomes.
Don't miss these expert insights!
🎧 Listen now: buff.ly/41zTGp8
#Leusm #ALLsm #ImmunoOnc #CTSM #TrialUpdate #BloodSky #Hemesky #HemOnc
Hear about the status of #CARTCell therapy in acute and chronic leukemias (ALL, AML, CLL) in our interview from #CART25 with Ulrich Jäger:
👉 https://buff.ly/3QhuKfw 👈
#Leusm #Leukemia #ALLsm #AMLsm #CLLsm #ImmunoOnc #HemOnc
Thank you to Valentín Ortiz-Maldonado for stopping by at #CART25 to share the results of the pivotal CART19-BE-02 trial investigating var-cel in adult R/R B-ALL!
Watch here:
👉 https://buff.ly/3EDdDCs
#ALLsm #Leusm #CARTCell #CTSM #TrialUpdate #ImmunoOnc #MedSky #BloodSky #HemeSky #HemeOnc
At #CART25 last week, Pere Barba of @vhio.bsky.social shared updated results from the FELIX trial, evaluating obe-cel in patients with R/R ALL.
Watch the interview here:
👉 https://buff.ly/40SDhKF 👈
#ALLsm #Leusm #CTSM #TrialUpdate #ImmunoOnc #MedSky #BloodSky #HemeSky #HemeOnc
In an interview from #ASH24, Sabina Chiaretti comments on the efficacy and tolerability of frontline ponatinib + blinatumomab for adult patients with Ph+ ALL, which was studied in the GIMEMA ALL2820 trial:
👉 https://buff.ly/3WPn0VD
#ALLsm #Leusm #CTSM #HemOnc #ImmunoOnc @ash.hematology.org
#CART25 | We caught up with Pere Barba who discussed all things CAR-T in ALL and gave an update on the FELIX trial 🩸 🎥
We can't wait to share this fantastic interview on vjhemonc.com! 🔜
#ALLsm #Leusm #ImmunoOnc #CARTCel
In an interview from #ASH24, @nitinjainmd.bsky.social of @mdanderson.bsky.social discusses an analysis assessing the safety of discontinuing TKIs in patients with Ph+ ALL not undergoing alloSCT.
Click here to watch:
👉 https://buff.ly/4hqSeue 👈
#ALLsm #Leusm #Leukemia #HemOnc
#ASH24 | Nicholas Short presents the updated results of a Phase II trial evaluating a chemo-free regimen combining blinatumomab + ponatinib for pts with newly diagnosed Ph+ ALL:
👉 https://buff.ly/3DbD7Wz 👈
#Leusm #ALLsm #ImmunoOnc #CTSM #TrialUpdate #HemeOnc #ASH24 @ash-hematology.bsky.social
14 pts treated so far. Good expansion in PB/CSF. G1 CRS 64%, no G2+ CRS, no ICANS. Median f/u 244 days, 1 pt w/ molR at 6m post-CAR T-cells. No deaths or other relapses. Very short f/u (only 2 post-12 months). Interesting approach for short course tx in hard-to-treat group of pts. 2/2 #ash24 #allsm
Dr. Ibrahim Aldoss from @cityofhope.bsky.social presents data on definitive CD19-targeted CAR T-cell therapy in pts ≥55 years w/ B-cell ALL in CR1. Lower disease burden pre-conditioning/LDC associated w/ ↓ toxicity and ↑ LFS. Pilot study schema as below. #ash24 #allsm 1/x
82% of the CART2 products were cryopreserved leftover cells; details as below. 50% of relapsed pts achieved MRD- CR w/ CART2. ↓ disease burden associated w/ better LFS/OS w/ CART2. Time from CART1 to CART2 not associated w/ outcome. May be effective bridge to alloHCT or further tx. 2/2 #ASH24 #allsm
Susana Rives from Hospital Sant Joan de Déu (Barecelona) presents on 2nd CAR T-cell infusion (CART2), CD19 or CD22 targeted, auto or allo, in pts w/ R/R B-ALL using a multicenter registry. 41/345 pts underwent CART2 post-CART1. 1/x #ash24 #allsm
